glp-1 amgen ADA: talks Repatha, hurdles as obesity plan advances Amgen (AMGN) Expands Obesity Strategy

Dawkins and Pratley note that while studies show people with obesity and type 2 diabetes experience significant weight loss on a GLP-1 agonist or dual agonist, people with type 2 diabetes experience slightly less weight loss compared with those with overweight and obesity without type 2 diabetes.1-3 Counseling Tips for RDs Despite the success of these classes of weight management medications, patients can receive anywhere from a little to a lot of information on how to optimize their use since a wide variety of clinicians, from primary care providers to obesity medicine experts, prescribe them

Designed for candidates with a BMI of 30 or above, our program combines the medically-supervised administration of weight loss shots with diet and exercise coaching for a healthier lifestyle

For both pills tested, researchers saw side effects similar to those associated with other GLP-1 drugs: some nausea, vomiting, diarrhea and constipation

Pricing for Eden, Ro, and Willow is based on each providers published rates as of April 2026

Diabetes 53: 654-662, 2004